Cogstate Limited
ABN 80 090 975 723

Level 2, 255 Bourke Street
Melbourne Victoria 3000
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

ASX Announcement

23 March 2020

Eisai launches Cogstate technology in Japan as digital brain performance tool

Eisai Co., Ltd (Tokyo) today announced the launch of "NouKNOW", a digital tool for self-assessment of brain health based upon technology created by Cogstate. The Japanese product launch will occur on 31 March 2020 and will initially target (i) municipalities providing health services to local residents and (ii) corporations providing health checks for employees.

A full copy of the press release is attached.

Background information in respect of the license to Eisai
On 28 August 2019, Cogstate announced that it had entered into an agreement with pharmaceutical company, Eisai Co., Ltd., to distribute Cogstate technology in Japan. Under the exclusive licensing agreement, Eisai will market Cogstate technology as a digital cognitive assessment tool for cognition in Japanese markets. The agreement specifically excludes clinical trials, where Cogstate will continue to market its offering independently.

Under the terms of the agreement Eisai:

- Provided an upfront royalty payment to Cogstate of US$1million;
- Invested approx. US$1.9 million in Cogstate ordinary shares;
- Is funding necessary product development activities to further tailor Cogstate solutions for the Japanese user base; and
- Is funding a commercial team in Japan.

Cogstate and Eisai will share profits equally after taking into account the associated cost of sales for the product in Japan. The agreement has an initial term of ten years, with performance criteria to maintain exclusivity at year 5 and 8.

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supporting the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate has recently entered into an exclusive licensing agreement with pharmaceutical company, Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. For more information, please visit www.cogstate.com.

For further information contact:
Brad O'Connor
Cogstate Chief Executive Officer
boconnor@cogstate.com